Global DNA methylation in a population with aflatoxin B1 exposure

Hui-Chen Wu1, Qiao Wang1, Hwai-I Yang2,3, Wei-Yann Tsai4,5, Chien-Jen Chen6,7, and Regina M Santella1,8,*

1Department of Environmental Health Sciences; Mailman School of Public Health of Columbia University; New York, NY USA; 2Graduate Institute of Clinical Medical Science; China Medical University; Taichung, Taiwan; 3Molecular and Genomic Epidemiology Center; China Medical University Hospital; Taichung, Taiwan; 4Department of Biostatistics; Mailman School of Public Health of Columbia University; New York, NY USA; 5Department of Statistics; National Cheng Kung University; Tainan City, Taiwan; 6Graduate Institute of Epidemiology and Preventive Medicine; College of Public Health; National Taiwan University; Taipei, Taiwan; 7Genomics Research Center; Academia Sinica; Taipei, Taiwan; 8Herbert Irving Comprehensive Cancer Center; Columbia University Medical Center; New York, NY USA

Keywords: aflatoxin B1, DNA methylation, Hepatitis B virus, global DNA methylation, LINE-1, Sat2, white blood cell

Abbreviations: 8-oxodG, 8-oxodeoxyguanosine; AFB1, aflatoxin B1; Anti-HCV, antibodies to hepatitis C virus; BMI, body mass index; CSP, cancer screening program; ELISA, enzyme-linked immunosorbent assay; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; WBC, white blood cell

We previously reported that global DNA hypomethylation, measured as Sat2 methylation in white blood cells (WBC), and aflatoxin B1 (AFB1) exposure were associated with increased hepatocellular carcinoma risk. In this study, we assessed the association between AFB1 exposure and global DNA methylation. We measured LINE-1 and Sat2 methylation in WBC DNA samples from 1140 cancer free participants of the Cancer Screening Program (CSP) cohort. Blood and urine samples were used to determine the level of AFB1-albumin (AFB1-Alb) adducts and urinary AFB1 metabolites. In continuous models, we found reverse associations of urinary AFB1 with LINE-1 and Sat2 methylation. The odds ratio (OR) per 1 unit increase were 1.12 (95% CI = 1.03–1.22) for LINE-1 and 1.48 (95% CI = 1.10–2.00) for Sat2 methylation. When compared with subjects in the highest quartile of LINE-1, we found that individuals in the 2nd and 3rd quartiles were less likely to have detectable AFB1-Alb adducts, with ORs (95% CI) of 0.61 (0.40–0.93), 0.61 (0.40–0.94), and 1.09 (0.69–1.72), respectively. The OR for detectable AFB1-Alb was 1.81 (95% CI = 1.15–2.85) for subjects in the lowest quartile of Sat2 methylation. The OR for detection of urinary AFB1, for those with LINE-1 methylation in the lowest quartile compared with those in the highest quartile was 1.87 (95% CI = 1.15–3.04). The corresponding OR was 1.75 (95% CI = 1.08–2.82) for subjects in the lowest quartile of Sat2 methylation. The association between AFB1 exposure, exposure and global DNA methylation may have implications for the epigenetic effect of AFB1 on hepatocellular carcinoma development and also suggests that changes in DNA methylation may represent an epigenetic biomarker of dietary AFB1 exposure.

Introduction

Aflatoxins are naturally occurring mycotoxins produced by only a few *Aspergillus* species of which *A. flavus* and *A. parasiticus* are the most important; they live in hot and humid conditions. Aflatoxins commonly contaminate foods such as peanuts, grain and corn. Aflatoxin B1 (AFB1), the most potent hepatocarcinogen, can induce principally G→T mutations, including a p53 codon 249 hotspot mutation.1-3 Once ingested, AFB1 is metabolized by the cytochrome P-450 system at the 8,9-vinyl bond to produce an unstable reactive intermediate, AFB1-8,9-epoxide.4 This intermediate can bind covalently to DNA,5 forming AFB1-guanine adducts, and to protein, forming AFB1-albumin and other protein adducts.6,7 Much epidemiological evidence suggests that dietary exposure to AFB1 is an important contributor to the high incidence of hepatocellular carcinoma (HCC) in Eastern and South-Eastern Asia, including Taiwan (reviewed in ref. 8).

We previously applied two biological markers of AFB1 exposure, AFB1-albumin (AFB1-Alb) adducts and urinary AFB1 metabolites, to understand the role of AFB1 exposure on risk of HCC.9-12 Using data on the analyses of urine and albumin samples banked up to 12 y before diagnosis in the Cancer Screening Program (CSP) in Taiwan, our results suggested that high dietary exposed to AFB1 was associated with 1.5–1.8 times the risk of HCC compared with low exposure.12 Other prospective studies also showed strong associations between biological markers of AFB1 exposure in serum or urine and risk of subsequent HCC.13-16 DNA methylation may play an important role in causing disease by silencing genes through hypermethylation or activating genes through hypomethylation.17 In addition to gene-specific DNA methylation, lower genome-wide aberrant DNA methylation (also referred to as global methylation) in regions that are normally methylated, such as repeats or transposable elements, can lead to genomic instability and altered gene transcription,
impacting normal growth and development. DNA methylation typically occurs in CpG dinucleotides and up to 80% of CpG dinucleotides occurs in repetitive sequences. There are different types of repetitive sequences scattered throughout the genome (e.g., satellite repeats, SINE [short interspersed nuclear element], and LINEs [long interspersed nuclear elements]). Changes in DNA methylation patterns are one of the most common molecular alterations in HCC tumor tissues. Global hypomethylation is associated with genomic instability and an increased number of mutational events (reviewed in ref. 28). We recently conducted a prospective case-control study nested within the CSP cohort where there is a high incidence of HCC and high AFB$_1$ exposure, and found that global hypomethylation in baseline white blood cell (WBC) DNA was significantly associated with increased HCC risk later in life. Whether dietary exposure to AFB$_1$ is associated with WBC DNA methylation change has not been evaluated. Using bi-specimens and data from 1140 cancer free participants in the CSP cohort, we tested the hypothesis that AFB$_1$ exposure is associated with a global decrease in methylation level in WBC DNA.

**Results**

Table 1 shows the levels of LINE-1 and Sat2 methylation by subjects’ characteristics. Males had statistically significant lower Sat2 methylation compared with females (4.6 ± 0.6 vs. 4.8 ± 0.5 for logSat2; $P = 0.0002$). There was no difference in LINE-1 and Sat2 methylation in relation with smoking, alcohol or anti-HCV status. Individuals positive for HBsAg showed statistically higher Sat2 methylation than negative individuals (4.7 ± 0.6 vs. 4.6 ± 0.6 for logSat2; $P = 0.001$).

Table 2 shows the distributions of biomarkers of AFB$_1$ by subject's characteristics. Both older age and being positive for HBsAg were associated with high AFB$_1$-Alb adducts but not urinary AFB$_1$. Male gender and anti-HCV status were associated with both biomarkers of AFB$_1$. Level of urinary AFB$_1$ was associated with smoking and alcohol drinking.

The odds ratios (ORs) from logistic regression models of the association between DNA methylation and detection of AFB$_1$-Alb adducts are presented in Table 3. We did not find any association between detection of AFB$_1$-Alb adducts and LINE-1 or Sat2 methylation as continuous variables. When LINE-1 methylation levels were stratified into quartiles based on all values, we observed a U shaped association with AFB$_1$-Alb adducts; the adjusted ORs for detection of AFB$_1$-Alb adducts were 0.61 (95% CI = 0.40–0.93), 0.61 (95% CI = 0.40–0.94) and 1.09 (95% CI = 0.69–1.72) for subjects with adducts in the 3rd, 2nd, and 1st quartile of LINE-1, respectively, compared with those in the highest quartile. The ORs were 1.15 (95% CI = 0.76–1.76), 1.03 (95% CI = 0.68–1.56) and 1.81 (95% CI = 1.15–2.85) for subjects in the 3rd, 2nd, and lowest quartile of Sat2 methylation, respectively, compared with subjects in the highest.

The association of DNA methylation with detection of urinary AFB$_1$ is given in Table 4. We observed evidence of a reverse association between urinary AFB$_1$ and methylation in LINE-1 and Sat2. The association using a continuous measure was statistically significant (OR per 1 unit decrease in LINE-1 methylation = 1.12, 95% CI = 1.03–1.22). When LINE-1 methylation was modeled in quartiles, we found individuals with detectable urinary AFB$_1$ were more likely to have lower levels of LINE-1 methylation. The adjusted OR for those in the second and lowest quartile of LINE-1 methylation compared with those in the highest quartile were 1.70 (95% CI = 1.07–2.69) and 1.87 (95% CI = 1.15–3.04), respectively. We also found an association between Sat2 methylation and detection of urinary AFB$_1$, as a continuous or categorical variable; the OR per 1 unit decrease in natural log Sat2 methylation was 1.48 (95% CI = 1.10–2.00). The ORs were 1.33 (0.85–2.07), 1.26 (0.80–1.97) and 1.75 (1.08–2.82) for those in the 3rd, 2nd, and lowest quartiles, compared with subjects in the highest quartile.

Table 1. Mean levels of LINE-1 and Sat2 by subjects’ characteristics

| Variable | N  | % Methylation (Mean ± SD) |
|----------|----|--------------------------|
| **Age**  |    |                          |
| Below Mean (≤51) | 508 | 75.5 ± 2.1 | 4.6 ± 0.6 |
| Above Mean (>51) | 632 | 75.5 ± 2.1 | 4.6 ± 0.6 |
| **BMI (kg/m²)** |    |                          |
| Below Mean (≤24.1) | 591 | 75.4 ± 2.1 | 4.6 ± 0.6 |
| Above Mean (>24.1) | 549 | 75.6 ± 2.1 | 4.6 ± 0.6 |
| **Gender** |    |                          |
| Female | 129 | 75.8 ± 1.8 | 4.6 ± 0.5 |
| Male | 1011 | 75.4 ± 2.2 | 4.6 ± 0.6 |
| **Smoking** |    |                          |
| No | 603 | 75.6 ± 2.0 | 4.6 ± 0.6 |
| Yes | 535 | 75.5 ± 2.2 | 4.6 ± 0.6 |
| **Alcohol** |    |                          |
| No | 925 | 75.6 ± 2.0 | 4.6 ± 0.6 |
| Yes | 212 | 75.3 ± 2.4 | 4.6 ± 0.7 |
| **HBsAg** |    |                          |
| Negative | 686 | 75.4 ± 2.1 | 4.6 ± 0.6 |
| Positive | 454 | 75.7 ± 2.1 | 4.7 ± 0.6 |
| **Anti-HCV** |    |                          |
| Negative | 983 | 75.5 ± 2.1 | 4.6 ± 0.6 |
| Positive | 123 | 75.4 ± 2.0 | 4.6 ± 0.6 |

Smoking data missing on 2 subjects. Alcohol data missing on 3 subjects. Anti-HCV data missing on 34 subjects. One-way ANOVA test of the differences in the methylation markers among groups.
mechanisms leading to development of HCC are not fully understood. The biotransformation of AFB1 to the highly reactive exo-8,9-epoxide is the most well-known toxic and carcinogenic pathway. In addition to the formation of adducts, it is believed that AFB1 acts as a carcinogen by mechanisms that include the formation of reactive oxygen species leading to increased hepatic oxidative damage. In our previous studies, we found that AFB1 exposure was positively associated with level of oxidative DNA damage in humans as measured by urinary 8-oxo-7,8-dihydro-guanine (8-oxoG) as well as urinary 15-F2t-isoprostanes, a marker of lipid peroxidation. Oxidative DNA damage such as 8-oxoG can interfere with the ability of methyltransferases to interact with DNA, thus resulting in global decreased DNA methylation. Long-term exposure to oxidative stress has been shown to increase oxidative damage to methylated cytosine residues and depletion in the level of 5-methylcytosine in repeated elements.

The effects of changes in epigenetic marks can be as profound as DNA sequence mutations and may increase susceptibility to disease including cancer. Previous studies indicated

| Table 2. Distribution of subject’s characteristics by levels of biomarkers of AFB1 exposure |
|---------------------------------------------------------------|
| Variable | AFB1-albumin | Urinary AFB1 |
| | Q1 (n = 284) | Q2 (n = 289) | Q3 (n = 284) | Q4 (n = 282) | P |
| Age, y (Mean ± SD) | 50.0 ± 9.8 | 50.2 ± 9.9 | 52.1 ± 8.8 | 52.0 ± 8.0 | 0.004 |
| BMI, kg/m² (Mean ± SD) | 24.2 ± 2.9 | 24.0 ± 3.4 | 24.3 ± 3.4 | 23.9 ± 3.4 | 0.45 |
| Gender | | | | | |
| Female/Male | 24/261 | 42/247 | 41/243 | 22/260 | 0.009 |
| Smoking | | | | | |
| No/Yes | 155/130 | 158/129 | 154/130 | 136/146 | 0.33 |
| Alcohol | | | | | |
| No/Yes | 229/54 | 247/42 | 225/59 | 224/57 | 0.20 |
| HBsAg | | | | | |
| Negative/Positive | 217/68 | 127/162 | 168/116 | 174/108 | 0.0001 |
| Gender | | | | | |
| Female/Male | 259/25 | 230/46 | 240/27 | 254/25 | 0.01 |
| Smoking | | | | | |
| No/Yes | 62/222 | 25/258 | 24/265 | 18/266 | <0.0001 |
| Alcohol | | | | | |
| No/Yes | 176/106 | 170/113 | 143/146 | 114/170 | <0.0001 |
| HBsAg | | | | | |
| Negative/Positive | 163/121 | 183/100 | 172/117 | 168/116 | 0.32 |
| Anti-HCV | | | | | |
| Negative/Positive | 228/42 | 249/26 | 259/22 | 247/33 | 0.03 |

One-way ANOVA test of the differences in the markers of AFB1 among groups.

**Discussion**

We previously reported that global DNA hypomethylation in WBC DNA was significantly associated with increased HCC risk later in life. In this study, we found that decreased LINE-1 or Sat2 methylation was associated with dietary exposed to AFB1. Those in the higher quartiles of AFB1-Alb adducts had lower LINE-1 and Sat2 methylation than those in the first quartile. Compared with individuals with undetectable AFB1 biomarkers, those with detectable AFB1-Alb adducts or urinary AFB1, metabolites were more likely to be in the lowest quartile of LINE-1 or Sat2 methylation. Our results provide data in humans supporting the hypothesis that exposure to AFB1 contributes to decreased global DNA methylation and that AFB1 may play a role in HCC by altering global DNA methylation status.

Dietary exposure to AFB1 is one of the major risk factors for HCC in regions of high incidence. Despite the fact that most prospective studies, including ours, report strong associations between biological markers of AFB1, exposure in serum or urine and risk of subsequent HCC (reviewed in ref. 8), the underlying
In agreement with our previous study, we found individuals positive for HBsAg had statistically significant higher Sat2 methylation, compared with those negative for HBsAg and individuals negative for HBsAg and with detectable AFB1 exposure had the lowest Sat2 methylation compared with other groups. An in vitro study demonstrated that exposure to HBV leads to upregulation of host DNA methyltransferase genes, resulting in increased methylation in host and viral DNA. To better understand the role of HBV infection and the combined effect of HBV with AFB1 exposure on HCC risk, it is important to characterize genome-wide DNA methylation among individuals with HBV infection alone and individuals with both HBV infection and AFB1 exposure.

Men have a higher incidence of HCC than women (reviewed in ref. 49). Many studies have found that LINE-1 methylation was higher in males than in females (reviewed in ref. 50). We found males had lower Sat2 methylation than females. The conflicting data might be due to differences in the distribution of other risk factors including diet that differ by gender in the Taiwanese population. In our present study population, males had higher value of urinary AFB1 metabolites (60.5 ± 44.9 fmol/mL for males verses 38.9 ± 43.1 for females, \( P < 0.0001 \)). In general, AFB1-Alb adducts have been recognized as long-term markers of AFB1 exposure. Because albumin adducts are as long lived as albumin, which has a half-life of 21 d in humans, they provide information on accumulated exposure over a period of 2 to 3 mo.\(^7,51\) The long-term stability of AFB1-Alb adducts has been

|     | % Methylation | AFB1-Alb adducts |     |     |     |
|-----|---------------|------------------|-----|-----|-----|
|     |               | Undetectable     | Detectable | OR(95%CI) | AdjOR(95%CI) |
| LINE-1 |             |                 |             |     |     |
| 1 unit decrease | 241 | 899 | 1.00(0.93–1.07) | 1.01(0.94–1.01) |
| Above mean (>75.5) | 119 | 459 | 1.0 | 1.0 |
| Below mean (≤75.5) | 122 | 440 | 1.00(0.70–1.24) | 1.04(0.77–1.40) |
| Quartile |     |     |     |     |     |
| Q4 (>76.79) | 50 | 242 | 1.0 | 1.0 |
| Q3 (75.50–76.79) | 69 | 217 | 0.65(0.43–0.98) | 0.61(0.40–0.93) |
| Q2 (74.20–75.49) | 74 | 217 | 0.61(0.41–0.91) | 0.61(0.40–0.94) |
| Q1 (<74.20) | 48 | 223 | 0.96(0.62–1.48) | 1.09(0.69–1.72) |

P trend = 0.71
P trend = 0.75

| logSat2 | 1 unit decrease | 237 | 880 | 1.08(0.84–1.37) | 1.26(0.96–1.66) |
|--------|----------------|-----|-----|----------------|----------------|
| Above mean (>4.6) | 128 | 472 | 1.0 | 1.0 |
| Below mean (≤4.6) | 113 | 427 | 1.03(0.77–1.36) | 1.17(0.87–1.58) |
| Quartile |     |     |     |     |     |
| Q4 (>5.0) | 62 | 219 | 1.0 | 1.0 |
| Q3 (4.7–5.0) | 62 | 225 | 1.03(0.69–1.53) | 1.15(0.76–1.76) |
| Q2 (4.3–4.6) | 69 | 209 | 0.86(0.58–1.27) | 1.03(0.68–1.56) |
| Q1 (<4.3) | 44 | 227 | 1.46(0.95–2.24) | 1.81(1.15–2.85) |

P trend = 0.20
P trend = 0.03

OR adjusted for age, sex, smoking, alcohol, HBsAg status, and anti-HCV status.

Significant geographic variation in the methylation status of various CpG islands was observed when the methylation status of 12 CpG islands in 85 HCC tumors from various geographic locations was investigated, indicating environmental factors may induce DNA methylation aberrations in HCC tumors. We previously measured promoter methylation in candidate genes in 83 HCC tumors and examined its relationship to AFB1 exposure. We found hypermethylation in promoter regions of tumor suppressor genes including p16INK4A and RASSF1A, correlated with AFB1-DNA adducts in liver tissues and AFB1-Alb adducts. The association of RASSF1A methylation and AFB1-DNA adducts was also reported in another study. These data also suggest that exposure to dietary AFB1 may alter methylation status of key genes involved in development of HCC.

In agreement with our previous study, we found individuals positive for HBsAg had statistically significant higher Sat2 methylation, compared with those negative for HBsAg and individuals negative for HBsAg and with detectable AFB1 exposure had the lowest Sat2 methylation compared with other groups. An in vitro study demonstrated that exposure to HBV leads to upregulation of host DNA methyltransferase genes, resulting in increased methylation in host and viral DNA. To better understand the role of HBV infection and the combined effect of HBV with AFB1 exposure on HCC risk, it is important to characterize genome-wide DNA methylation among individuals with HBV infection alone and individuals with both HBV infection and AFB1 exposure.

Men have a higher incidence of HCC than women (reviewed in ref. 49). Many studies have found that LINE-1 methylation was higher in males than in females (reviewed in ref. 50). We found males had lower Sat2 methylation than females. The conflicting data might be due to differences in the distribution of other risk factors including diet that differ by gender in the Taiwanese population. In our present study population, males had higher value of urinary AFB1 metabolites (60.5 ± 44.9 fmol/mL for males verses 38.9 ± 43.1 for females, \( P < 0.0001 \)). In general, AFB1-Alb adducts have been recognized as long-term markers of AFB1 exposure. Because albumin adducts are as long lived as albumin, which has a half-life of 21 d in humans, they provide information on accumulated exposure over a period of 2 to 3 mo.\(^7,51\) The long-term stability of AFB1-Alb adducts has been
Second, studies have shown that global DNA methylation differs by blood cell type. \textsuperscript{57,58} However, we measured LINE-1 and Sat2 by MethyLight in 48 women with DNA available from four different sources including white blood cells, granulocytes, mononuclear cells and lymphoblastoid cell lines. We found methylation levels were not significantly different among four cell types.\textsuperscript{59} It is unclear if the associations we found in the present study were due to the differences in the distributions of cell types among people with different AFB\textsubscript{1} exposure. Currently only one animal study showed percentage changes in T cells and B cells with aflatoxin dosing.\textsuperscript{60} Studies are needed to show that AFB\textsubscript{1} exposure does not change blood cell type human populations. Finally, although we observed a significant association of global DNA hypomethylation with AFB\textsubscript{1} exposure, the magnitude of change in the level of DNA methylation is small and the biological significance is unclear.

Despite these limitations, this study has numerous strengths. First, we applied antibody-based methods for measurement of AFB\textsubscript{1} exposure including AFB\textsubscript{1}-albumin and urinary AFB\textsubscript{1} metabolites, which provide more accurate assessment of AFB\textsubscript{1} exposure at the individual level than food questionnaires. Second, this study design allowed us to investigate the associations of methylation levels of different types of DNA repetitive elements with AFB\textsubscript{1} exposure in a population with high AFB\textsubscript{1} exposure and high prevalence of HCC, providing potential biological mechanisms for the process of hepatocarcinogenesis.

| % Methylation | Undetectable | Detectable | UR(95%CI) | AdjOR(95%CI) |
|---------------|--------------|------------|-----------|-------------|
| LINE-1        | 1 unit decrease | 197         | 943       | 1.09(1.03–1.20) | 1.12(1.03–1.22) |
|               | Above mean (>75.5) | 123         | 455       | 1.0         | 1.0         |
|               | Below mean (≤75.5) | 74          | 488       | 1.78(1.30–2.44) | 1.75(1.25–2.44) |
|               | Quartile      | Q4 (>76.79) | 57        | 235         | 1.0         | 1.0         |
|               | Q3 (75.50–76.79) | 66          | 220       | 0.81(0.54–1.21) | 1.03(0.67–1.56) |
|               | Q2 (74.20–75.49) | 41          | 250       | 1.48(0.95–2.29) | 1.70(1.07–2.69) |
|               | Q1 (<74.20) | 33          | 238       | 1.75(1.10–2.79) | 1.87(1.15–3.04) |
|               | logSat2       | 1 unit decrease | 195     | 922         | 1.67(1.26–2.21) | 1.48(1.10–2.00) |
|               | Above mean (>4.6) | 120         | 480       | 1.0         | 1.0         |
|               | Below mean (≤4.6) | 77          | 463       | 1.50(1.10–2.06) | 1.36(0.98–1.90) |
|               | Quartile      | Q4 (>5.0) | 62        | 219         | 1.0         | 1.0         |
|               | Q3 (4.7–5.0) | 51          | 236       | 1.31(0.87–1.98) | 1.33(0.85–2.07) |
|               | Q2 (4.3–4.6) | 47          | 231       | 1.39(0.91–2.12) | 1.26(0.80–1.97) |
|               | Q1 (<4.3) | 35          | 236       | 1.91(1.21–3.00) | 1.75(1.08–2.82) |

OR adjusted for age, sex, smoking, alcohol, HBsAg status, and anti-HCV status.
In summary, we found an inverse association between biomarkers of AFB, and biomarkers of global DNA methylation. These results strongly suggest that AFB, exposure may result in a decrease in DNA methylation globally. Our results provide information on the application of biomarkers in human populations at high-risk for cancer and that AFB,-induced global DNA hypomethylation may, in addition to the formation of AFB,-DNA adducts, have an important role in AFB, carcinogenicity.

Materials and Methods

Study cohort. Subjects are from the CSP cohort recruited in Taiwan. This study was approved by Columbia University’s Institutional Review Board as well as the Research Ethics Committee of the College of Public Health, National Taiwan University. Written informed consent was obtained from all subjects and strict quality controls and safeguards were used to protect confidentiality. The cohort characteristics have been described in detail previously. Briefly, this cohort was originally set up for the evaluation of cancer screening efficacy. Study subjects were voluntary participants in a free cancer screening program implemented in seven urban townships in Taiwan. Individuals who were between 30 and 65 year old were recruited between July 1990 and June 1992 with a total of 12,020 males and 11,923 females. All participants were administrated a structured questionnaire to obtain epidemiological information on socio-demographic characteristics, habits of alcohol intake and cigarette smoking, health history and family history of cancer. Habitual cigarette smoking was defined as having smoked >4 d/wk for at least six months. Information about duration and intensity was also obtained. Habitual alcohol intake was defined as drinking alcohol containing products >4 d/wk for at least six months. For each subject, 15 ml of blood and spot urine were collected, and transported on dry ice to a central laboratory at the National Taiwan University. WBC, plasma and red blood cells were separated and all biospecimens were stored at −70 °C. Hepatitis B virus surface antigen (HBsAg), was tested by radio-immunoassay (Abbott Laboratories); antibody against hepatitis C virus (anti-HCV) was tested by enzyme immunoassay using commercial kits (Abbott Laboratories).

Currently, there is passive follow up of the cohort. New cases are detected by computerized data linkage with profiles on the national cancer registry and death certification systems in Taiwan. The overall follow-up rate is 98%. Through June 2008, 305 cases were identified. We randomly selected controls from cohort subjects who were not affected with HCC through the follow-up period by matching to each case by age (± 5 y), gender, residential township and date of recruitment (± 3 mo). We applied a nested case-control study design to examine the etiology of AFB, exposure by measuring biomarker of AFB, on HCC risk. Baseline WBCs and urine were shipped to Columbia University on dry ice for determination of biomarkers of AFB, exposure and global DNA methylation.

Study subjects. For this study, we used information from 1140 cancer free participants in the CSP cohort for whom we previously measured biomarkers of AFB, exposure including AFB,-Alb adducts and AFB, metabolites and biomarkers of global DNA methylation including LINE-1 and Sat2 in baseline samples.

AFB,-albumin adducts in blood and AFB, metabolites in urine. Plasma samples were assayed for albumin adducts by enzyme-linked immunosorbent assay (ELISA) as previously described. Briefly, 50 μl of albumin extracts, equivalent to 200 μg albumin, were added to plates previously coated with 3 ng of AFB, epoxide-modified human serum albumin (HSA). Polyclonal antiserum #7 was used at 1:2 × 10^3 dilution and the secondary antiserum, goat anti-rabbit IgG-alkaline phosphatase conjugate, was used at 1:750 dilution. Concentrations of AFB,-Alb adducts were determined using a standard curve of serially diluted AFB, epoxide-modified HSA that had been enzymatically digested. Samples with less than 20% inhibition were considered undetectable and assigned a value of 0.01 fmol/μg. Two controls samples were analyzed with each batch of test samples, a pooled sample of plasma from non-smoking US subjects and a positive control of serum from a rat treated with 1.5 mg AFB,. The coefficient of variation (CV) of the mean of the two controls was 20% (n = 13).

Urines were assayed essentially as described previously. Seppak urine extracts (50 μl) were added to plates previously coated with 3 ng of AFB, epoxide-modified bovine serum albumin. AF8E11 was used at 1:1500 dilution and the secondary antiserum, goat anti-mouse alkaline phosphatase was used at 1:1000 dilution. AF8E11 mainly reacts with AFB, but there is significant cross-reactivity with a number of aflatoxin derivatives, including AFB, AFM1, AFG1, and AFQ1. Concentrations of urinary metabolites were determined using a standard curve of serially diluted AFB,. Samples with less than 20% inhibition were considered undetectable and assigned a value of 1 fmol/ml. A pooled sample of urine from 5 controls was used as a quality control and analyzed with each batch of test samples. The CV was 10% (n = 5).

DNA extraction and bisulfite treatment. Genomic DNA was extracted from WBCs by a salting out procedure. Cells were lysed with SDS in a nuclei lysis buffer and treated with RNase A (final 133 μg/mL) and RNase T1 (final 20 units/mL) to remove RNA. Proteins were co-precipitated with NaCl (330 μL of saturated NaCl added per 1 mL solution) by centrifugation. Genomic DNA was recovered from the supernatant by precipitation with 100% ethanol, washed in 70% ethanol, and dissolved in the Tris-EDTA buffer.

Aliquots of DNA (500 ng) were bisulfite-treated with the EZ DNA methylation kit (Zymo Research). The DNA was resuspended in 20 μL of distilled water and stored at −20 °C until use.

MethyLight assay. We used the sequences of probe and forward and reverse primers of Sat2-M1 described in Weisenberger et al. PCR was performed in a 10 μL reaction volume with 0.3 μM forward and reverse PCR primers, 0.1 μL probe, 3.5 μM MgCl2, using the following PCR program: 95 °C for 10 min, then 55 cycles of 95 °C for 15 sec, followed by 60 °C for 1 min. Assays were run on an ABI Prism 7900 Sequence Detection System (LifeTechnologies). The MethyLight data were expressed as percent of methylated reference (PMR) values and are the mean of duplicates.
PMR = 100% * 2 exp – [ΔDelta Ct (target gene in sample – control gene in sample) – ΔDelta Ct (100% methylated target gene in reference sample – control gene in reference sample)] Ten percent of subjects were assayed in duplicate, and the inter assay CV for the Sat2 MethylLight assay was 1.0%.

**Pyrosequencing assay.** Pyrosequencing for LINE-1 methylation levels was performed using PCR and sequencing primers as previously described, with minor modifications to the original protocol. Briefly, PCR was performed in a 25 μL reaction mix containing 50 ng bisulfite-converted DNA, 1× Pyromark PCR Master Mix (Qiagen), 1× Coral Load Concentrate (Qiagen), and 0.2 μM forward and reverse primers, using the following PCR program: 95 °C for 15 min, then 44 cycles of 95 °C for 30 sec followed by 56 °C for 30 sec and 72 C for 30 sec, with a final extension at 72 °C for 10 min. Following amplification, the biotinylated PCR products were purified and incubated with the sequencing primer designed to bind adjacent to the CpG sites of interest. Pyrosequencing was conducted using a PyroMark Q24 instrument (Qiagen), with subsequent quantitation of methylation levels determined with the PyroMark Q2 1.010 software. Percent methylation within a sample was subsequently determined by averaging across all three interrogated CpG sites in the analysis. Ten percent of subjects were assayed in duplicate, and the inter assay CV for the LINE-1 pyrosequencing assay was 0.5%.

The laboratory investigator who performed all assays was blinded to epidemiologic data.

**Statistical methods.** We used one-way ANOVA to test if there is any difference in methylation among groups and performed the Tukey Studentized Range comparisons with Bonferroni correction to determine which groups are different. Because Sat2 methylation was not normally distributed, all statistical analyses used data after natural log transformation. To estimate associations with AFB exposure, we used logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We modeled the associations adjusting for age (years, continuous), sex, HBsAg (Yes vs. No), Anti-HCV (Yes vs. No), smoking (Ever vs. Never), and alcohol consumption (Ever vs. Never) in models. Markers of global DNA methylation were assessed both as continuous measures and as quartiles, based on the distribution among all subjects to accommodate possible nonlinear associations. All analyses were performed with SAS software 9.0 (SAS Institute). All statistical tests were based on two-tailed probability.

**Disclosure of Potential Conflicts of Interest**
No potential conflicts of interest were disclosed.

**Acknowledgments**
This work was supported by National Institutes of Health grants RO1ES005116, P30ES009809, and P30CA13696.

**References**
1. Bressac B, Kew M, Wands J, Orruk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429-31; PMID:1672732; http://dx.doi.org/10.1038/350429a
2. Hsu IC, Mercalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-8; PMID:1849234; http://dx.doi.org/10.1038/350427a
3. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57:3471-7; PMID:9270015
4. Forrester LM, Neal GE, Judd DJ, Glancy MJ, Wolf CR. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci U S A 1990; 87:8306-10; PMID:2122459; http://dx.doi.org/10.1073/pnas.87.21.8306
5. Essigmann JM, Croy RG, Nadzan AM, Budoff WF Jr., Renhold VN, Büch G, et al. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A 1977; 74:1870-4; PMID:2066709; http://dx.doi.org/10.1073/pnas.74.5.1870
6. Gallagher EP, Wienkers IC, Stapleton PL, Kunze KL, Eaton DL. Role of human microsomal and human complementary DNA-expressed cytochromes P450IA2 and P450IA4 in the bioactivation of aflatoxin B1. Cancer Res 1994; 54:101-8; PMID:8261428
7. Sabbonni G, Skipper PL, Büchi G, Tannenbaum SR. Identification and characterization of the major serum aflatoxin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 1987; 8:819-24; PMID:3111739; http://dx.doi.org/10.1093/carcin/8.6.819
8. Wu HC, Santiell R. The role of aflatoxins in hepatocellular carcinoma. Hepat Mon 2012; 12:10 HICC:e7238; PMID:23162603; http://dx.doi.org/10.5812/hepatmon.7238
9. Wang LY, Hatch MC, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67:620-5; PMID:8782648; http://dx.doi.org/10.1002/(SICI)1097-0215(19960904)67:5<620::AID-IJC3-5.CO;2-W
10. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24:38-42; PMID:8707279; http://dx.doi.org/10.1002/hep.100240108
11. Sun Z, Li P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30:379-83; PMID:10421643; http://dx.doi.org/10.1002/hep.1003060204
12. Wu HC, Wang Q, Yang HJ, Ahsan H, Tasi WY, Wang YL, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2009; 18:486-53; PMID:19273485; http://dx.doi.org/10.1158/1055-9965.EPI.08-0607
13. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Liu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Cancer Res 1999; 59:128-34; PMID:8659516
14. Yu MW, Lien JP, Chiu YH, Santella RM, Liao YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997; 27:320-30; PMID:9288667; http://dx.doi.org/10.1016/S0168-8278(97)95017-X
15. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28; PMID:12042769
16. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400-13; PMID:12154403; http://dx.doi.org/10.1038/sj.onc.1205651
17. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al.; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921; PMID:11237011; http://dx.doi.org/10.1038/35057062
18. Shen J, Wang S, Zhang YJ, Kappel M, Wu HC, Kibria MG, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012; 55:1799-808; PMID:22234943; http://dx.doi.org/10.1002/hep.25569
19. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002; 35:85-92; PMID:12325038; http://dx.doi.org/10.1002/mc.10076
20. Zhang YJ, Ahsan H, Chen Y, Yuan JM, Lunn RM, Wang LY, Rossner P Jr., Chen Y, Agrawal M, Wang Q, Wang L, et al. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer 2006; 119:985-91; PMID:16570275; http://dx.doi.org/10.1002/ijc.21699

©2013 Landes Bioscience. Do not distribute.
1. Lamber HM, Shi CY, Shen Y, Ong CN. Detection of TET1 by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer 2003; 103:440-4; PMID:13650825.

2. Santella RM. Global DNA methylation levels in white blood cells: relations to age, gender, and DNA methylation of offspring. J Nutr 2002; 132:1304-50; PMID:12049833; http://dx.doi.org/10.1093/jn/132.5.1304.

3. Bailey EA, Jey RB, Stone MP, Harris TM, Essigmann JM. Mutational properties of the primary aflatoxin-B1-DNA adduct. Proc Natl Acad Sci U S A 1993; 90:3153-9; PMID:8643667; http://dx.doi.org/10.1073/pnas.90.7.3153.

4. Shih LM, Ahuja N, Lee BL, Shi CY. Aflatoxin B1-induced 8-hydroxydeoxyguanosine formation in rat hepatic DNA. Carcinogenesis 1995; 16:419-22; PMID:7785375; http://dx.doi.org/10.1003/carci.1995.419.

5. Shih LM, Shi CY, Chen YQ. DNA binding domain (MBD) of methyl-CpG binding protein 2 in hepatoma cell lines. Int J Cancer 2007; 120:12-20; PMID:17164894; http://dx.doi.org/10.1002/ijc.22279.

6. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010; 78(Suppl 1):172-9; PMID:20616601; http://dx.doi.org/10.1159/000325575.

7. Teruya-Feldstein J, Chen Y, Ahsan H, Lunn RM, Chen SJ, Wogan GN, et al. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1 in human urine. Cancer Epidemiol Biomarkers Prev 2011; 20:71-8; PMID:20931675; http://dx.doi.org/10.1158/1055-9966.EPI-09-1361.

8. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010; 78(Suppl 1):172-9; PMID:20616601; http://dx.doi.org/10.1159/000325575.

9. Bhat CH, Chen CJ, Levin B, Ji BT, Yang GY, Hsu SW, et al. Urinary aflatoxin levels, hepatobiliary virus infection and hepatocellular carcinoma in Taiwan. Int J Cancer 1993; 54:931-4; PMID:8392983; http://dx.doi.org/10.1002/ijc.2910540411.

10. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005; 33:6683-93; PMID:15993332; http://dx.doi.org/10.1093/nar/gki987.

11. Ang YS, Estévez MRH, Doshi K, Kondo Y, Tajara EH, Isa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32:e38; PMID:14973332; http://dx.doi.org/10.1093/nar/ggh332.